Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, Eylea, a medicine that treats wet age-related macular degeneration. The therapy is facing stiff competition, biosimilar and otherwise, that is eating into its market share.However, Regeneron is constantly looking for its next billion-dollar medicine. And a recent deal it made with a smaller drugmaker helped it beef up its pipeline by acquiring an asset in the hottest therapeutic area right now: weight management. Is Regeneron stock a buy now?Image source: Getty Images.Continue reading
Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, Eylea, a medicine that treats wet age-related macular degeneration. The therapy is facing stiff competition, biosimilar and otherwise, that is eating into its market share.
However, Regeneron is constantly looking for its next billion-dollar medicine. And a recent deal it made with a smaller drugmaker helped it beef up its pipeline by acquiring an asset in the hottest therapeutic area right now: weight management. Is Regeneron stock a buy now?
Image source: Getty Images.
